Veracyte, Inc. logo

Veracyte, Inc.

12V GR

Veracyte, Inc.GRGreece Composite

17.60

EUR
-0.30
(-1.68%)
Veracyte, Inc.
12V:GR
(Greece Composite)

Recent

price

17.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

Business
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Company News

  • What Makes Veracyte (VCYT) a Lucrative Investment?